NCCN Guidelines® Insights: B-cell lymphomas, version 5.2021: Featured updates to the NCCN Guidelines Guidelines
| Authors: | Zelenetz, A. D.; Gordon, L. I.; Chang, J. E.; Christian, B.; Abramson, J. S.; Advani, R. H.; Bartlett, N. L.; Budde, L. E.; Caimi, P. F.; De Vos, S.; Dholaria, B.; Fakhri, B.; Fayad, L. E.; Glenn, M. J.; Habermann, T. M.; Hernandez-Ilizaliturri, F.; Hsi, E.; Hu, B.; Kaminski, M. S.; Kelsey, C. R.; Khan, N.; Krivacic, S.; LaCasce, A. S.; Lim, M.; Narkhede, M.; Rabinovitch, R.; Ramakrishnan, P.; Reid, E.; Roberts, K. B.; Saeed, H.; Smith, S. D.; Svoboda, J.; Swinnen, L. J.; Tuscano, J.; Vose, J. M.; Dwyer, M. A.; Sundar, H. |
| Title: | NCCN Guidelines® Insights: B-cell lymphomas, version 5.2021: Featured updates to the NCCN Guidelines |
| Abstract: | In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease. © 2021 Harborside Press. All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 19 |
| Issue: | 11 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2021-11-01 |
| Start Page: | 1218 |
| End Page: | 1230 |
| Language: | English |
| DOI: | 10.6004/jnccn.2021.0054 |
| PROVIDER: | scopus |
| PUBMED: | 34781267 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2022 -- Source: Scopus |
